Skip to main content

Table 1 Discounted life-years, QALYs and incremental cost-effectiveness ratios of chemotherapy in the Austrian setting versus Canadian setting

From: Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online

  Austrian setting Canadian setting
Risk category Chemo LYs QALYs Costs (€) ICER (€/QALY) LYs QALYs Costs (€) ICER (€/QALY)
AO ODX
Low Low No 15.51 12.04 11,021 D 15.36 11.93 10,088 D
Yes 15.16 11.65 23,383 15.14 11.69 11,817
Low Int. No 14.96 11.61 12,063 D 14.85 11.52 11,279 61,861
Yes 15.05 11.57 23,608 15.04 11.61 16,562
Low High No 12.06 9.31 17,520 3361 12.07 9.32 17,368 3118
Yes 14.73 11.31 24,240 14.73 11.37 23,743
Low N/A No 14.80 11.48 9230 566,277 14.69 11.40 8347 3768
Yes 14.97 11.50 20,554 14.96 11.55 8925
Int. Low No 15.21 11.80 11,557 D 15.10 11.72 10,708 D
Yes 15.02 11.54 23,641 15.01 11.59 12,105
Int. Int. No 13.71 10.62 14,421 13,504 13.69 10.60 13,872 4094
Yes 14.77 11.34 24,163 14.78 11.40 17,150
Int. High No 9.45 7.25 21,733 698 9.51 7.30 22,401 416
Yes 14.61 11.21 24,500 14.60 11.26 24,049
Int. N/A No 12.63 9.77 13,372 4790 12.63 9.76 12,927 548
Yes 14.78 11.35 20,960 14.79 11.41 13,833
High Low No 15.21 11.81 11,561 D 15.09 11.71 10,721 D
Yes 15.03 11.55 23,666 15.01 11.59 12,116
High Int. No 13.76 10.66 14,471 14,496 13.66 10.58 13,969 3940
Yes 14.75 11.33 24,143 14.77 11.40 17,186
High High No 9.43 7.23 21,815 676 9.48 7.27 22,474 400
Yes 14.60 11.21 24,502 14.59 11.26 24,068
High N/A No 12.09 9.34 14,257 3097 12.08 9.33 14,078 2816
Yes 14.88 11.43 20,729 14.87 11.48 20,121
  1. Abbreviations: AO Adjuvant!Online, ODX OncotypeDX, Int. Intermediate, LYs life years, QALYs quality-adjusted life-years, ICER incremental cost-effectiveness ratio, N/A ODX test not applied